Cargando…

Cardiovascular outcomes and safety of SGLT2 inhibitors in chronic kidney disease patients

BACKGROUND: Sodium–glucose co-transporter 2 (SGLT2) inhibitors provide cardiovascular protection for patients with heart failure (HF) and type 2 diabetes mellitus (T2DM). However, there is little evidence of their application in patients with chronic kidney disease (CKD). Furthermore, there are inco...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Xiutian, Wang, Jiali, Lin, Yongda, Yao, Kaijin, Xie, Yina, Zhou, Tianbiao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10690412/ https://www.ncbi.nlm.nih.gov/pubmed/38047108 http://dx.doi.org/10.3389/fendo.2023.1236404

Ejemplares similares

Gut microbiota: a newly identified environmental factor in systemic lupus erythematosus
por: Yao, Kaijin, et al.
Publicado: (2023)

An overview of the efficacy and signaling pathways activated by stem cell-derived extracellular vesicles in diabetic kidney disease
por: Lin, Yongda, et al.
Publicado: (2022)

Mesenchymal stem cells: A new therapeutic tool for chronic kidney disease
por: Wang, Jiali, et al.
Publicado: (2022)

Signaling Pathways of Podocyte Injury in Diabetic Kidney Disease and the Effect of Sodium-Glucose Cotransporter 2 Inhibitors
por: Chen, Xiutian, et al.
Publicado: (2022)

Comparative Cardiovascular Outcomes of SGLT2 Inhibitors in Type 2 Diabetes Mellitus: A Network Meta-Analysis of Randomized Controlled Trials
por: Jiang, Yu, et al.
Publicado: (2022)

SGLT2 Inhibitors and Kidney Outcomes in Patients with Chronic Kidney Disease
por: Kanduri, Swetha R., et al.
Publicado: (2020)

Association of SGLT2 inhibitors with cardiovascular, kidney, and safety outcomes among patients with diabetic kidney disease: a meta-analysis
por: Kaze, Arnaud D., et al.
Publicado: (2022)

Effects of SGLT2 inhibitors on hepatic fibrosis and steatosis: A systematic review and meta-analysis
por: Zhou, Peipei, et al.
Publicado: (2023)

The expanding role of SGLT2 inhibitors beyond glucose-lowering to cardiorenal protection
por: Brown, Emily, et al.
Publicado: (2021)

Cardiovascular Benefits With Favorable Renal, Amputation and Hypoglycemic Outcomes of SGLT-2 Inhibitors in Type 2 Diabetes From the Asian Perspective: A Population-Based Cohort Study and Systematic Review
por: Yang, Chun-Ting, et al.
Publicado: (2022)

Effects of GLP-1 agonists and SGLT2 inhibitors during pregnancy and lactation on offspring outcomes: a systematic review of the evidence
por: Muller, Dion R. P., et al.
Publicado: (2023)

Effects and mechanisms of SGLT2 inhibitors on the NLRP3 inflammasome, with a focus on atherosclerosis
por: Yang, Liu, et al.
Publicado: (2022)

The impact of SGLT2 inhibitors on αKlotho in renal MDCK and HK-2 cells
por: Wolf, Lisa, et al.
Publicado: (2023)

Therapeutic Targeting of SGLT2: A New Era in the Treatment of Diabetes and Diabetic Kidney Disease
por: Shaffner, James, et al.
Publicado: (2021)

Comparison the effects of finerenone and SGLT2i on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus: A network meta-analysis
por: Li, Xuefeng, et al.
Publicado: (2022)

Effects of SGLT2 Inhibitors and GLP-1 Receptor Agonists on Renin-Angiotensin-Aldosterone System
por: Puglisi, Soraya, et al.
Publicado: (2021)

Case Report: Metreleptin and SGLT2 Inhibitor Combination Therapy Is Effective for Acquired Incomplete Lipodystrophy
por: Nagayama, Ayako, et al.
Publicado: (2021)

Comprehensive review of SGLT2 inhibitors’ efficacy through their diuretic mode of action in diabetic patients
por: Lam-Chung, Cesar Ernesto
Publicado: (2023)

Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis
por: Donnan, Jennifer R, et al.
Publicado: (2019)

Renal effects of SGLT2 inhibitors in cardiovascular patients with and without chronic kidney disease: focus on heart failure and renal outcomes
por: Gronda, Edoardo G., et al.
Publicado: (2022)

Safety of four SGLT2 inhibitors in three chronic diseases: A meta-analysis of large randomized trials of SGLT2 inhibitors
por: Qiu, Mei, et al.
Publicado: (2021)

Mini Review: Effect of GLP-1 Receptor Agonists and SGLT-2 Inhibitors on the Growth Hormone/IGF Axis
por: Cignarelli, Angelo, et al.
Publicado: (2022)

Effects of SGLT2 Inhibitors on Renal Outcomes in Patients With Chronic Kidney Disease: A Meta-Analysis
por: Li, Ning, et al.
Publicado: (2021)

GLP-1 RAs and SGLT-2 Inhibitors for Insulin Resistance in Nonalcoholic Fatty Liver Disease: Systematic Review and Network Meta-Analysis
por: Yan, Hongle, et al.
Publicado: (2022)

Risk of infections in patients with NAFLD and Type 2 Diabetes under treatment with SGLT2 inhibitors and relationship with liver outcomes: A retrospective case-control study
por: Bañares, Juan, et al.
Publicado: (2022)

The Effects of DPP-4 Inhibitors, GLP-1RAs, and SGLT-2/1 Inhibitors on Heart Failure Outcomes in Diabetic Patients With and Without Heart Failure History: Insights From CVOTs and Drug Mechanism
por: Pan, Xiaohui, et al.
Publicado: (2020)

The Extraglycemic Effect of SGLT-2is on Mineral and Bone Metabolism and Bone Fracture
por: Dong, Bingzi, et al.
Publicado: (2022)

Is There a Diabetes–Kidney–Heart Continuum? Perspectives From the Results of the Cardiovascular and Renal Outcome Clinical Trials With SGLT2 Inhibitors
por: Bao, Liwen, et al.
Publicado: (2021)

SGLT2 Inhibitors in Diabetic and Non-Diabetic Chronic Kidney Disease
por: Podestà, Manuel Alfredo, et al.
Publicado: (2023)

Comparison of cardiovascular outcomes between SGLT2 inhibitors in diabetes mellitus
por: Suzuki, Yuta, et al.
Publicado: (2022)

Efficacy and safety of GLP-1 receptor agonists versus SGLT-2 inhibitors in overweight/obese patients with or without diabetes mellitus: a systematic review and network meta-analysis
por: Ma, Hong, et al.
Publicado: (2023)

Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: A Meta-analysis
por: McGuire, Darren K., et al.
Publicado: (2020)

Interaction Between Non-Insulin Glucose-Lowering Medication and Exercise in Type 2 Diabetes Mellitus – New Findings on SGLT2 Inhibitors
por: Brinkmann, Christian
Publicado: (2021)

Fournier’s Gangrene: A Coexistence or Consanguinity of SGLT-2 Inhibitor Therapy
por: Chowdhury, Tutul, et al.
Publicado: (2022)

Antioxidant Roles of SGLT2 Inhibitors in the Kidney
por: Llorens-Cebrià, Carmen, et al.
Publicado: (2022)

Systematic review and meta-analysis of the effect of SGLT-2 inhibitors on microvascular outcomes in patients with type 2 diabetes: a review protocol
por: Dorsey-Treviño, Edgar Gerardo, et al.
Publicado: (2018)

FRI106 Outcomes Of SGLT2 Inhibitors In Patients With Heart Failure With Or Without Diabetes In A Tertiary Care Center In Saudi Arabia
por: Alqifari, Saleh F, et al.
Publicado: (2023)

Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes
por: Clar, Christine, et al.
Publicado: (2012)

Fasting-Induced Natriuresis and SGLT: A New Hypothesis for an Old Enigma
por: Heyman, Samuel N., et al.
Publicado: (2020)

Renal Protection with SGLT2 Inhibitors: Effects in Acute and Chronic Kidney Disease
por: Bailey, Clifford J., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_7iqask55g6socasigkgscf4cgu